UK Bags More COVID-19 Vaccines And Backs J&J, Novavax Trials
Deal For 90 Million Doses
With the Janssen and Novavax deals, the UK has now secured access to six different candidates across four different vaccine types.
You may also be interested in...
A first look at the clinical data for Novavax’s COVID-19 vaccine suggests it can produce strong antibody responses while being well tolerated.
The UK BioIndustry Association has welcomed the government’s fresh investment in COVID-19 vaccine manufacturing capacity, while Sanofi and GSK are striking European and US deals for their vaccine candidate. A number of potential therapies are also being developed, including products based on interferon and hyperimmune globulin, but Roche/Chugai’s Actemra (tocilizumab) looks like a non-runner.
The UK's vaccine strategy spread its bets over three candidates so far, as the country also looks to prove its world-class status in life sciences research and manufacturing.